Tags:AppBioTechBuildingChemicalDrugLivingOptimizePhysicalSmartTechnology
Ambrx Inc., is a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code. Ambrx technology uses an expanded genetic code to incorporate synthetic amino acids into protein, all completed within a living cell. These synthetic amino acids enable the creation of Precision Biologics, an exciting new class of therapeutics with broad application and potential. This includes next-generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as smart cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease.
Location: United States, California, San Diego
Member count: 51-200
Total raised: $297M
Founded date: 2003

Investors 5

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
23.11.2020-$200M-prnewswire...
05.08.2016-$45M-finsmes.co...
06.07.2006-$52M-socaltech....

Mentions in press and media 15

DateTitleDescriptionCategoryAuthorSource
19.10.2022Biotech la...It’s been no se­cret that this...-Tyler Patc...endpts.com...
07.01.2021Ambrx Appo... SAN DIEGO, Jan. 7, 2021 /PRN...--prnewswire...
24.11.2020Af­ter 5 q...The first time San Diego biote...FinancingJason Mastendpts.com...
23.11.2020$200M inve...Investors in the $200 million ...--medcitynew...
23.11.2020Ambrx has ...---connect.or...
10.11.2020 Ambrx ...San Diego-based biopharmaceuti...--socaltech....
10.11.2020Ambrx Land... SAN DIEGO, CA, Ambrx has ann...--vcnewsdail...
09.11.2020Ambrx Clos... SAN DIEGO, Nov. 9, 2020 /PRN...--prnewswire...
09.11.2020Ambrx has ...---connect.or...
09.11.2020Ambrx Clos...Ambrx Inc., a San Diego, CA-ba...USA-finsmes.co...
Show more